Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of RP, Oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study.

Hegewisch-Becker, S., Arnold, D., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Bartan, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher-Schick, A., Tannapfel, A., Quidde, J., Hinke, A., Schmoll, H.-J., Graeven, U., 2014.

Oncol Res Treat 37 (Suppl.5)(V327), 99 doi:10.1159/000368945